Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.
| Year | ID | Type | Category | Title | Authors |
|---|
| 2016 | DX32 | Poster | Disease Modification |
Risk Factors for Lymphopenia in Patients with Relapsing Remitting Multiple Sclerosis Treated with Dimethyl Fumarate |
Fabian Sierra Morales, MD, Igor Koralnik, MD and Jacob A. Sloane, MD PhD, Neurology, Beth Israel Deaconess Medical Center, Boston, MA |
| 2016 | DX33 | Poster | Disease Modification |
Efficacy and Safety of Ocrelizumab in Relapsing Multiple Sclerosis: Results of the Phase III, Interferon ß-1a-Controlled OPERA I and OPERA II Studies |
Fred Lublin, MD1, Douglas L Arnold, MD2,3, Amit Bar-Or, MD, FRCPC3, Giancarlo Comi, MD4, Stephen L Hauser, MD5, Krzysztof Selmaj, MD, PhD6, Anthony Traboulsee, MD, FRCPC7, Peter Chin, MD8, Paulo Fontoura, MD, PhD9, Hideki Garren, MD, PhD9, Gaelle Klingelschmitt, MSc9, Donna Masterman, MD8, Ludwig Kappos, MD, PhD10 and Hans-Peter Hartung, MD, FRCP, FAAN, FANA11, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)NeuroRx Research, Montreal, QC, Canada, (3)McGill University, Montreal, QC, Canada, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)University of California, San Franscisco, CA, (6)Medical University of Lodz, Lodz, Poland, (7)University of British Columbia, Vancouver, BC, Canada, (8)Genentech, Inc., South San Francisco, CA, (9)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (10)University Hospital Basel, Basel, Switzerland, (11)Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany |
| 2016 | DX34 | Poster | Disease Modification |
Effect of Ocrelizumab on Clinical Disability in Two Identical Phase III, Double-Blind, Double-Dummy, Interferon ß-1a–Controlled Studies |
Fred Lublin, MD1, Douglas L Arnold, MD2,3, Amit Bar-Or, MD, FRCPC3, Giancarlo Comi, MD4, Hans-Peter Hartung, MD, FRCP, FAAN, FANA5, Stephen L Hauser, MD6, Krzysztof Selmaj, MD, PhD7, Anthony Traboulsee, MD, FRCPC8, Peter Chin, MD9, Paulo Fontoura, MD, PhD10, Hideki Garren, MD, PhD10, Gaelle Klingelschmitt, MSc10, Donna Masterman, MD9 and Ludwig Kappos, MD, PhD11, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)NeuroRx Research, Montreal, QC, Canada, (3)McGill University, Montreal, QC, Canada, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, (6)University of California, San Franscisco, CA, (7)Medical University of Lodz, Lodz, Poland, (8)University of British Columbia, Vancouver, BC, Canada, (9)Genentech, Inc., South San Francisco, CA, (10)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (11)University Hospital Basel, Basel, Switzerland |
| 2016 | DX35 | Poster | Disease Modification |
Relapse Rates of Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon ß-1a vs Oral Disease-Modifying Drugs in the Real World |
Chris M Kozma, PhD1, Frederick Munschauer, MD2 and Amy L Phillips, PharmD2, (1)CK Consulting Associates, LLC, Saint Helena Island, SC, (2)EMD Serono, Inc., Rockland, MA |
| 2016 | DX36 | Poster | Disease Modification |
Effect of Oral Fingolimod Treatment on Brain Volume Loss in Patients with Relapsing–Remitting Multiple Sclerosis Estimated Using Bayesian Methodology |
Guosheng Yin, PhD1, Xiangyi Meng, PhD2 and M. Zahur Islam, PhD2, (1)The University of Hong Kong, Hong Kong, Hong Kong, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2016 | DX37 | Poster | Disease Modification |
Oral Therapy Switches: How Many Patients Are Returning to Injectable Therapies? |
Janet Moores, RN, BN, MBA, University of Calgary MS Clinic, Calgary, AB, Canada |
| 2016 | DX38 | Poster | Disease Modification |
Methylprednisolone Treatment, Patient Reported Tolerance and Efficacy |
Jeffrey B English, MD1, Sophia Strickland, pre-medical student2 and Patrick J English, pre-business student2, (1)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (2)Clinical Research, Multiple Sclerosis Center of Atlanta, Atlanta, GA |
| 2016 | DX39 | Poster | Disease Modification |
Clinical Outcomes in Discontinuation and Restart of Natalizumab |
Jeffrey B English, MD1, Debra K Johnson, RN2, Mitzi J. Williams, MD1 and Donna M Court, MN, RN2, (1)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (2)Clinical Research, Multiple Sclerosis Center of Atlanta, Atlanta, GA |
| 2016 | DX40 | Poster | Disease Modification |
Global Reach Webinars Enrich Nursing Scope of Practice |
Jennifer Smrtka, MSN, ARNP-BC, MSCN, Neurology, University of Miami, Miami, FL and Lori Mayer, DNP, MSN, RN, MSCN, MS Clinic of Central Texas/Central Texas Neurology Consultants, Round Rock, TX |
| 2016 | DX41 | Poster | Disease Modification |
Brain Health: Time Matters in Multiple Sclerosis – Developmental Process and Objectives of International Consensus Policy Recommendations |
Kathleen Costello, MS, ANP-BC, MSCN, Vice President, Healthcare Access, National Multiple Sclerosis Society, New York, NY, Helmut Butzkueven, MBBS, PhD, Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia, Suhayl Dhib-Jalbut, MD, Department of Neurology, RUTGERS Robert Wood Johnson Medical School, New Brunswick, NJ, Jeremy Hobart, PhD FRCP, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom of Great Britain and Northern Ireland, Gisela Kobelt, PhD, European Health Economics, Mulhouse, France, George Pepper, ., Shift.ms, Leeds, United Kingdom of Great Britain and Northern Ireland, Maria Pia Sormani, PhD, Biostatistics Unit, University of Genoa, Genoa, Italy, Christoph Thalheim, ., Patient Advocate in Multiple Sclerosis, Brussels, Belgium, Anthony Traboulsee, MD, FRCPC, Department of Medicine, University of British Colombia, Vancouver, BC, Canada, Timothy Vollmer, MD, Department of Neurology, University of Colorado Denver, Aurora, CO and Gavin Giovannoni, MBBCh, PhD, Queen Mary University London, Barts and The London School of Medicine, London, United Kingdom; Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom of Great Britain and Northern Ireland |
| 2016 | DX42 | Poster | Disease Modification |
Infusion-Related Reactions With Ocrelizumab in the Phase III Double-Blind, Double-Dummy, Interferon ß-1a-Controlled OPERA I and OPERA II Studies |
Krzysztof Selmaj, MD, PhD1, Douglas L Arnold, MD2,3, Amit Bar-Or, MD, FRCPC2, Giancarlo Comi, MD4, Hans-Peter Hartung, MD, FRCP, FAAN, FANA5, Stephen L Hauser, MD6, Fred Lublin, MD7, Anthony Traboulsee, MD, FRCPC8, Nicole Mairon, MD9, Peter Chin, MD10, Paulo Fontoura, MD, PhD9, Hideki Garren, MD, PhD9, Gaelle Klingelschmitt, MSc9, Donna Masterman, MD10 and Ludwig Kappos, MD, PhD11, (1)Medical University of Lodz, Lodz, Poland, (2)McGill University, Montreal, QC, Canada, (3)NeuroRx Research, Montreal, QC, Canada, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, (6)University of California, San Franscisco, CA, (7)Icahn School of Medicine at Mount Sinai, New York, NY, (8)University of British Columbia, Vancouver, BC, Canada, (9)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (10)Genentech, Inc., South San Francisco, CA, (11)University Hospital Basel, Basel, Switzerland |
| 2016 | DX43 | Poster | Disease Modification |
A Phase III, Open-label Study to Evaluate the Effect of Ocrelizumab on Immune Responses in Patients With Relapsing Multiple Sclerosis |
Laurie Millar, PhD, Carrie Li, PhD, Henry Bennett, BSc and Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd., Basel, Switzerland |
| 2016 | DX44 | Poster | Disease Modification |
Incidence of Infusion-Associated Reactions Decreases with Subsequent Courses of Alemtuzumab: 5-Year Data from the Care-MS Extension Study |
Lori Mayer, DNP, MSN, RN, MSCN1, Edward J. Fox, MD, PhD1, Christopher LaGanke, MD2, Bhupendra Khatri, MD3, Ann D Bass, MD4, David H Margolin, MD, PhD5, Linda Kasten, MA6 and Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN7, (1)Central Texas Neurology Consultants, Round Rock, TX, (2)North Central Neurology Associates, Cullman, AL, (3)Wheaton Franciscan Regional MS Center, Milwaukee, WI, (4)Neurology Center of San Antonio, San Antonio, TX, (5)Genzyme, a Sanofi company, Cambridge, MA, (6)PROMETRIKA, LLC, Cambridge, MA, (7)Neurology Associates, PA, Maitland, FL |
| 2016 | DX45 | Poster | Disease Modification |
Lymphopenia in Multiple Sclerosis Patients Treated with Delayed-Release Dimethyl Fumarate: Analysis of 2 Electronic Health Record Databases in the US |
Madé Wenten, PhD, MPH, Teesta Soman, MD, MBA, Cathy Lally, MSPH, Maneesh Juneja, BSc, Susan Eaton, MSPH, MT (ASCP), Claudia Prada, MD, PhD and Anne Dilley, BA, MPH, PhD, Biogen, Cambridge, MA |
| 2016 | DX46 | Poster | Disease Modification |
Alemtuzumab Causes Significant, Transient, Post-Infusion Thrombocytopenia and Other Non-Autoimmune Cytopenias Following Initial and Subsequent Courses |
Roochi S Ghodasara, MD1, Madelyn B Rarick, BSN1, Miranda C Mosley, BS1, Rachel A Morgan, BA1, S.R. Sparrow Smith, BS, MA1, Laurel Kagan, NP1, Daniel Kantor, MD2,3, Joy Derwenskus, DO, MS1 and Samuel F. Hunter, MD, PhD1,2, (1)Advanced Neurosciences Institute, Franklin, TN, (2)NeuroNexus Center – Novel Pharmaceutics Institute, Franklin, TN, (3)Kantor Neurology, Coconut Creek, FL |
| 2016 | DX47 | Poster | Disease Modification |
Key Results from PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod Versus Platform Injectable Disease-Modifying Therapies in Early Relapsing–Remitting MS |
Mark Cascione, MD1, Bruce AC Cree, MD, PhD2, Daniel Wynn, MD3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4 and Nadia Tenenbaum, MD4, (1)Tampa Neurology Associates, South Tampa Multiple Sclerosis Center, South Tampa, FL, (2)University of California San Francisco, San Francisco, CA, (3)Consultants in Neurology MS Center, Northbrook, IL, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2016 | DX48 | Poster | Disease Modification |
Final Outcomes from the Teriflunomide TOWER Extension Study: Up to 6 Years of Follow-up (Core Plus Extension) in Patients with Relapsing Forms of MS |
Mark S Freedman, MD1, Ludwig Kappos, MD2, Giancarlo Comi, MD3, Aaron E Miller, MD4, Jerry Wolinsky, MD5, Karthinathan Thangavelu, PhD6, Philippe Truffinet, MD7, Myriam Benamor, MD7, Pascal Rufi, MD7 and Paul O’Connor, MD8, (1)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)University Hospital Basel, Basel, Switzerland, (3)University Vita-Salute San Raffaele, Milan, Italy, (4)Icahn School of Medicine at Mount Sinai, New York, NY, (5)University of Texas Health Science Center at Houston, Houston, TX, (6)Genzyme, a Sanofi company, Cambridge, MA, (7)Genzyme, a Sanofi company, Chilly-Mazarin, France, (8)University of Toronto, Toronto, ON, Canada |
| 2016 | DX49 | Poster | Disease Modification |
JC Virus Antibody Seropositivity Index Decreases with Reduced Infusion Frequency in Natalizumab-Treated Multiple Sclerosis Patients |
Michael A Mercurio, MD1, Michael Y Ko, MD2, Roumen Balabanov, MD3, Jennifer A Strong, MS3 and Dusan Stefoski, MD2, (1)Neurology, Rush University Medical Center, Chicago, IL, (2)Rush University Medical Center, Chicago, IL, (3)Rush University Multiple Sclerosis Center, Chicago, IL |
| 2016 | DX50 | Poster | Disease Modification |
A Retrospective Assessment of Real-World Discontinuation Rates in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate |
Michelle A Allan, RN BA Nursing GCert MS1 and Lindsay Grant, B.Pharm1,2, (1)Monash Neurology, Monash Health, Melbourne, Australia, (2)Medical, Biogen, Sydney, Australia |
| 2016 | DX51 | Poster | Disease Modification |
Real-World Comparison of Relapse Rates in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies |
Aaron Boster, MD1, Jacqueline Nicholas, MD, MPH2, Ning Wu, Ph.D.3, Wei-Shi Yeh, PhD3, Monica A Fay, PharmD4, Michael R Edwards, PhD5, Ming-Yi Huang, PhD3 and Andrew Lee, PhD3, (1)OhioHealth Neurological Physicians, Columbus, OH, (2)Health Economics & Outcomes Research, Novartis Pharmaceutical Corporation, East Hanover, NJ, (3)Global Health Economics and Outcomes Research, Biogen, Cambridge, MA, (4)US Medical Affairs, Biogen, Weston, MA, (5)Global Medical Affairs, Biogen, Cambridge, MA |
| 2016 | DX52 | Poster | Disease Modification |
Assessing the Incidence of Elevation in Eosinophils with the Use of Dimethyl Fumarate in Multiple Sclerosis |
Demetrios Konstas, MD1, Natalie K Moreo, MD1, Chetan P Gandhy, MD1, Michelle Lyman, MSII2, Doris Deng, MSII2, Robert Soares, BS1, Steven Aradi, MD3 and Derrick S Robertson, MD1, (1)Neurology, University of South Florida, Tampa, FL, (2)University of South Florida College of Medicine, Tampa, FL, (3)Neurology, University of Pennslyvania Perelman School of Medicine, Philadelphia, PA |
| 2016 | DX53 | Poster | Disease Modification |
Assessing the Incidence of Lymphopenia with the Use of Dimethyl Fumarate in Multiple Sclerosis |
Demetrios Konstas, MD1, Natalie K Moreo, MD1, Chetan P Gandhy, MD1, Doris Deng, MSII2, Michelle Lyman, MSII2, Robert Soares, BS1 and Derrick S Robertson, MD1, (1)Neurology, University of South Florida, Tampa, FL, (2)University of South Florida College of Medicine, Tampa, FL |
| 2016 | DX54 | Poster | Disease Modification |
The Use of Delayed-Release Dimethyl Fumarate in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM): 6-Month Interim Analysis |
Nicholas Everage, PhD1, Claudia Prada, MD, PhD1, Shifang Liu, PhD1, Konstantin Balashov, MD, PhD, FAAN2, Richard Macdonell, MD, FRACP3, Jörg Windsheimer, MD4 and Kathryn Giles, MD, MSc, FRCPC5, (1)Biogen, Cambridge, MA, (2)Robert Wood Johnson Medical School, New Brunswick, NJ, (3)Department of Neurology, Austin Health, Univ. of Melbourne, Melbourne, Australia, (4)Praxis für Neurologie und Psychiatrie, Nürnberg, Germany, (5)Cambridge Memorial Hospital, Cambridge, ON, Canada |
| 2016 | DX55 | Poster | Disease Modification |
Lemtrada Infusion Experience: Neurology Infusion Vs Nonneurology Infusion Centers |
Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN, MS Center of Greater Orlando, Maitland, FL |
| 2016 | DX56 | Poster | Disease Modification |
Open-Label Phase III Extension Studies to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab in Relapsing MS and Primary Progressive MS |
Robert Kuhelj, PhD1, Gurpreet Deol-Bhullar, BSc, OT1, Monika Garas, PhD1, Peter Chin, MD2, Stephen L Hauser, MD3 and Xavier Montalban, MD, PhD4, (1)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (2)Genentech, Inc., South San Francisco, CA, (3)University of California, San Franscisco, CA, (4)Hospital Vall d’Hebron University, Barcelona, Spain |
| 2016 | DX57 | Poster | Disease Modification |
Serious Adverse Events, Autoimmunity, and Infections Following Alemtuzumab Therapy in a Large, High Disability, Treatment-Refractory MS Clinic Cohort |
Roochi S Ghodasara, MD1, Miranda C Mosley, BS1, Rachel A Morgan, BA1, S.R. Sparrow Smith, BS, MA1, Madelyn B Rarick, BSN1, Laurel Kagan, NP1, Daniel Kantor, MD1, Joy Derwenskus, DO, MS1 and Samuel F. Hunter, MD, PhD2, (1)Neurology, Advanced Neurosciences Institute, Franklin, TN, (2)NeuroNexus Center – Novel Pharmaceutics Institute, Franklin, TN |
| 2016 | DX58 | Poster | Disease Modification |
Long-Term Effect of Fingolimod on Disability: A Categorical Trend Analysis over 8 Years |
Shannon Ritter, MS1, Anthony T Reder, MD2, Daniela Piani Meier, PhD3, Davorka Tomic, PhD3 and Bruce AC Cree, MD, PhD4, (1)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (2)University of Chicago, Chicago, IL, (3)Novartis Pharma AG, Basel, Switzerland, (4)University of California San Francisco, San Francisco, CA |
| 2016 | DX59 | Poster | Disease Modification |
Oligodendrogenesis Via a Small Molecule Therapy for Treating Multiple Sclerosis Patients |
Steven H Nye, Ph.D., Discovery, ENDECE Neural, LLC, Mequon, WI and James G Yarger, Ph.D., ENDECE Neural, LLC, Mequon, WI |
| 2016 | DX60 | Poster | Disease Modification |
Alemtuzumab Infusion Experience |
Tania A Reyna, MD1, Tony Sharp, PA2, Cecilie Fjeldstad, PhD2, Jennifer Smith, PA2 and Gabriel Pardo, MD2, (1)Oklahoma Medical Research Foundation, Oklahoma City, OK, (2)MS Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK |
| 2016 | DX61 | Poster | Disease Modification |
Treatment Adherence, Persistence, and Compliance at 96 Weeks in MS Patients Using Rebismart® for Injection of Interferon β-1a |
Virginia Devonshire, MD, Department of Neurology, University of British Columbia, Vancouver, BC, Canada, Anthony Feinstein, MPhil, PhD, FRCP, Department of Psychiatry, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada and Alan Gillett, PhD, EMD Serono, Mississauga, ON, Canada |
| 2016 | DX62 | Poster | Disease Modification |
Infusion-Related Reactions in the Phase III Double-Blind, Placebo-Controlled ORATORIO Study of Ocrelizumab in Primary Progressive Multiple Sclerosis |
Xavier Montalban, MD, PhD1, Douglas L Arnold, MD2,3, Amit Bar-Or, MD, FRCPC2, Jérôme de Seze, MD, PhD4, Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath5, Bernhard Hemmer, MD6,7, Kottil Rammohan, MD8, Nicole Mairon, MD9, Peter Chin, MD10, Paulo Fontoura, MD, PhD9, Hideki Garren, MD, PhD9, Donna Masterman, MD10, Annette Sauter, MD9 and Jerry Wolinsky, MD11, (1)Vall d’Hebron University Hospital, Barcelon, Spain, (2)McGill University, Montreal, QC, Canada, (3)NeuroRx Research, Montreal, QC, Canada, (4)University Hospital of Strasbourg, Strasbourg, France, (5)Queen Mary University of London, London, United Kingdom of Great Britain and Northern Ireland, (6)Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, (7)Technische Universität München, Munich, Germany, (8)University of Miami, Miami, FL, (9)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (10)Genentech, Inc., South San Francisco, CA, (11)University of Texas Health Science Center at Houston, Houston, TX |
| 2016 | DX63 | Poster | Disease Modification |
Cuprizone Mouse Model of Demyelination: Environmental Enhancement Reverses Cognitive Deficits |
Zahra Almosawi, BSc, Amal Almahroos, Bsc, Reem Abdulla, Bsc, Ayman Mohamed, BSc, Hawra Alalwan, BSc, Ahmmed Almubarak, BSc, Fajer Alammadi, BSc, Amer Kamal, Professor and Ahmed Al-Mahrezi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain |
| 2016 | EG01 | Poster | Epidemiology and Genetics |
The Effect of Modifiable Risk Factors on Multiple Sclerosis Progression |
Aliza Ben-Zacharia, DNP, ANP, MSCN, Neurology, Mount Sinai Hospital, New York, NY |
| 2016 | EG02 | Poster | Epidemiology and Genetics |
Prolonged Vzv IgM Serum Seropositivity in Multiple Sclerosis Is Associated with New Sensory Symptoms, a Case Series |
Dolly B Roy, MD PhD, Neurology, Northridge Hospital Medical Center, Northridge, CA |
| 2016 | EG03 | Poster | Epidemiology and Genetics |
Associations Between Ambient Air Pollution with Biomarkers and Functional Outcomes in Pwms |
Elizabeth W. Triche, PhD, Department of Epidemiology, Brown University School of Public Health, Providence, RI, Jennifer A. Ruiz, DPT, Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT and Albert C. Lo, MD, PhD, Departments of Neurology and Engineering, Brown University, Providence, RI |
| 2016 | EG04 | Poster | Epidemiology and Genetics |
Dietary Supplement Use Among Persons with Multiple Sclerosis Seen at a Comprehensive Care Center |
Elizabeth W. Triche, PhD1,2, Carolyn J. St. Andre, BS1, Lindsay O. Tuttle, MPH1, Jennifer A. Ruiz, DPT1 and Albert C. Lo, MD, PhD1, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT |
| 2016 | EG05 | Poster | Epidemiology and Genetics |
Intrauterine Devices May be Associated with a Later MS Disease Onset |
Katelyn S. Kavak, MS1, Barbara E. Teter, PhD, MPH2, Caila B Vaughn, MPH1, Keith R Edwards, MD, FAAN3, Patricia K Coyle, MD3, Lore Garten, MD4, Malcolm Gottesman, MD5, Burk Jubelt, MD6, Ilya Kister, MD3, Lauren Krupp, MD7, Jessica F Robb, MD3, Robert Zivadinov, MD, PhD3 and Bianca Weinstock-Guttman, MD3, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)Department of Neurology, University at Buffalo, Buffalo, NY, (3)New York State Multiple Sclerosis Consortium, Buffalo, NY, (4)MS Center of Northeastern New York, Latham, NY, (5)Winthrop Comprehensive MS Care Center, Mineola, NY, (6)SUNY Upstate Medical University, Syracuse, NY, (7)NYU Langone Medical Center, New York, NY |
| 2016 | EG06 | Poster | Epidemiology and Genetics |
Exploration of Association of Menarche with Age at Onset of Pediatric Nmo |
Tanuja Chitnis, MD1, Jennifer Graves, MD, PhD2, Cody S Olsen, MS3, Jayne Ness, MD4, Lauren Krupp, MD5, Anita Belman, MD5, Moses Rodriguez, MD6, Jan Tillema, MD7, Tim Lotze, MD, PhD8, Mark Gorman, MD9, Leslie Benson, MD10, Bianca Weinstock-Guttman, MD11, Greg Aaen, MD12, John Rose, MD13, T. Charles Casper, PhD14 and Emmanuelle Waubant, MD, PhD2, (1)Massachusetts General Hospital for Children, Boston, MA, (2)UCSF Pediatric MS Center, San Francisco, CA, (3)Neurology, University of Utah, Salt Lake City, UT, (4)Alabama Pediatric MS Center, Birmingham, AL, (5)Lourie Center for Pediatric MS, Stony Brook Children’s Hospital, Stony Brook, NY, (6)Department of Neurology, Mayo Clinic, Rochester, MN, (7)Pediatric MS Center, Mayo Clinic, Rochester, MN, (8)Texas Children’s Hospital, Houston, TX, (9)Massachusetts General Hospital, Partners Pediatric MS Center, Boston, MA, (10)Boston Children’s Hospital, Boston, MA, (11)New York State Multiple Sclerosis Consortium, Buffalo, NY, (12)Department of Child Neurology, Loma Linda University, Loma Linda, CA, (13)Department of Neurology University of Utah and Neurovirology Research Laboratory VASLCHCS, Imaging and Neuroscience Center, Salt Lake City, UT, (14)Department of Pediatrics, University of Utah, Salt Lake City, UT |
| 2016 | NI01 | Poster | Neuroimaging and Neurophysiology |
Memory and Visual Attention Evaluation in People with Multiple Sclerosis |
Ana M Canzonieri, DRA, Mauricio O Bando Sr., Sr, Jean I Francisco, Sr, Fernanda M Marques, Sra and Lucas F.R dos Santos Sr., student, Research, ABEM . Brazilian Association Multiple Sclerosis, São Paulo, Brazil |
| 2016 | NI02 | Poster | Neuroimaging and Neurophysiology |
Conventional MRI Measures in Relation to Advanced MRI Measures in Multiple Sclerosis before and after Mesenchymal Stem Cell Transplantation |
Carol Swetlik, BA1, Sarah M Planchon, PhD, CCRP2, Jeffrey A Cohen, MD2 and Daniel Ontaneda, MD2, (1)Cleveland Clinic Lerner College of Medicine, Cleveland, OH, (2)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH |
CMSC Scholar © 2020 All rights Reserved | Proudly Created by Adapting Social
